Cross-topic event
GSK/Ionis hepatitis B drug bepirovirsen: ~20% “functional cure” in Phase 3, NEJM publication
May 29, 20262 reports
May 29, 2026
Sciencedesk view
GSK/Ionis hepatitis B drug bepirovirsen: ~20% “functional cure” in Phase 3, NEJM publication
ScienceAlert and the Associated Press reported on May 29, 2026, that bepirovirsen—an antisense oligonucleotide from GSK and Ionis—achieved a functional cure (su…
READ THE DAY'S DIGEST →
Sports/Healthdesk view
GSK/Ionis: bepirovirsen Phase 3 shows ~19% functional cure in chronic hepatitis B; FDA review ongoing
ScienceAlert (May 29, 2026) and GSK (May 28) report that in two Phase 3 B-Well trials (~1,838 adults), six months of bepirovirsen plus standard care led to a fu…
READ THE DAY'S DIGEST →